8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) held on July 19-22, 2015 at Vancouver, British Columbia, Canada

  1. Bunupuradah T, KiertiburanakulS, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawan S, Nimitvilai S, JirajariyavejS, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K on behalf of the LASA Study Group. Atazanavir/ritonavir 200/100 mg is non-inferior to atazanavir/ritonavir 300/100 mg in virologic suppressed HIV-infected Thai adults: a multicentre, randomized, open-label trial: LASA. (oral presentation)
  2. Sudjaritruk T, Bunupuradah T, Aurpibul L, Kosalaraksa P, Kurniati N, Puthanakit T. Prevalence of nonalcoholic fatty liver disease and liver fibrosis among perinatally HIV-infected Asian adolescents.
  3. Apornpong T, Sapsirisavat V, Putcharoen O, Kerr SJ, Phonphithak S, Thiansanguankul W, Wattanachanya L, Ruxrungtham K, and Avihingsanon A, on the behalf of HIV-NAT 006 study team. Prevalence and risk factor for low bone mineral density among HIV-infected patients in Thailand.
  4. Chongthawonsatid S, Keadpudsa S, Rerksirikul P, Klinbuayaem W, Kerr SJ, Avihingsanon A, Prasithsirikul W. Depression and Anxiety amongst HIV-infected individuals enrolled in a public sector antiretroviral programme in Thailand.
  5. Prasitsuebsai W, Teeraananchai S, Truong KH, Ananworanich J, Do VC, Nguyen LV, Kosalaraksa P, Kurniati N, Sudjaritruk T, Chokephaibulkit K, Singtoroj T, Kerr S, SohnAHon behalf of the TASER-Pediatrics Study. Treatment and resistance outcomes of Asian children on second-line antiretroviral therapy. (oral presentation)
  6. Late breaker: Squires K, Kityo C, Hodder S, Hagins D, Avihingsanon A, Plotnikova Y, Koenig E, Post F, Chen S, White K, Cao H, Cheng A, Szwarcberg J. Elvitegravir (EVG) /Cobicistat (COBI) /Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) is Superior to Ritonavir (RTV) Boosted Atazanavir (ATV) plus FTC/TDF in treatment naïve women with HIV-1 infection (WAVES Study). Poster No. MOLBPE08